 Thomas Beresford
Concepts (237)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 18 | 2023 | 821 | 3.390 |
Why?
| | Disulfiram | 6 | 2007 | 15 | 1.360 |
Why?
| | Alcohol Deterrents | 6 | 2007 | 19 | 1.350 |
Why?
| | Immunosuppressive Agents | 4 | 2019 | 854 | 1.240 |
Why?
| | Calcineurin | 3 | 2019 | 107 | 1.070 |
Why?
| | Cyclosporine | 3 | 2018 | 265 | 1.060 |
Why?
| | Cocaine-Related Disorders | 4 | 2017 | 136 | 0.950 |
Why?
| | Defense Mechanisms | 3 | 2014 | 23 | 0.910 |
Why?
| | Alcohol Drinking | 5 | 2018 | 833 | 0.890 |
Why?
| | Alcohol-Related Disorders | 4 | 2014 | 125 | 0.840 |
Why?
| | Antipsychotic Agents | 3 | 2017 | 208 | 0.780 |
Why?
| | Substance Withdrawal Syndrome | 2 | 2023 | 181 | 0.760 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2018 | 94 | 0.750 |
Why?
| | Aripiprazole | 3 | 2017 | 19 | 0.740 |
Why?
| | Cost of Illness | 2 | 2014 | 310 | 0.700 |
Why?
| | Liver Transplantation | 4 | 2018 | 768 | 0.660 |
Why?
| | Schizophrenia | 2 | 2017 | 441 | 0.580 |
Why?
| | Nervous System Diseases | 2 | 2019 | 277 | 0.560 |
Why?
| | Perphenazine | 1 | 2017 | 1 | 0.560 |
Why?
| | Dopamine Agents | 1 | 2017 | 21 | 0.550 |
Why?
| | Craving | 1 | 2017 | 38 | 0.540 |
Why?
| | Brain Injuries, Traumatic | 1 | 2022 | 400 | 0.490 |
Why?
| | Ego | 2 | 2006 | 10 | 0.490 |
Why?
| | Jurisprudence | 2 | 2005 | 16 | 0.440 |
Why?
| | Substance Abuse Treatment Centers | 2 | 2005 | 47 | 0.420 |
Why?
| | Hepatitis C | 3 | 2007 | 250 | 0.420 |
Why?
| | Ethanol | 4 | 2023 | 629 | 0.400 |
Why?
| | Cannabinoids | 1 | 2015 | 178 | 0.400 |
Why?
| | Psychotherapy | 1 | 2014 | 184 | 0.370 |
Why?
| | Models, Psychological | 1 | 2014 | 312 | 0.370 |
Why?
| | Brain | 2 | 2015 | 2852 | 0.360 |
Why?
| | Patient Compliance | 3 | 2007 | 607 | 0.350 |
Why?
| | Hippocampus | 2 | 2006 | 939 | 0.340 |
Why?
| | Tacrolimus | 1 | 2012 | 198 | 0.330 |
Why?
| | Sirolimus | 1 | 2012 | 276 | 0.320 |
Why?
| | Neurology | 1 | 2010 | 112 | 0.300 |
Why?
| | Cannabis | 1 | 2015 | 510 | 0.280 |
Why?
| | Inflammation | 1 | 2019 | 2891 | 0.280 |
Why?
| | Food Handling | 3 | 2016 | 65 | 0.280 |
Why?
| | Stearates | 1 | 2007 | 1 | 0.260 |
Why?
| | Humans | 39 | 2023 | 140898 | 0.260 |
Why?
| | Palmitic Acids | 1 | 2007 | 10 | 0.260 |
Why?
| | Oleic Acids | 1 | 2007 | 12 | 0.260 |
Why?
| | Pituitary ACTH Hypersecretion | 1 | 2006 | 11 | 0.260 |
Why?
| | Double-Blind Method | 4 | 2022 | 1978 | 0.260 |
Why?
| | Behavior, Addictive | 1 | 2007 | 88 | 0.250 |
Why?
| | Sick Role | 1 | 2006 | 19 | 0.250 |
Why?
| | Serum Albumin | 1 | 2007 | 152 | 0.240 |
Why?
| | Valproic Acid | 2 | 2022 | 45 | 0.240 |
Why?
| | Bipolar Disorder | 5 | 2006 | 274 | 0.240 |
Why?
| | Physician-Patient Relations | 1 | 2010 | 580 | 0.240 |
Why?
| | Mental Disorders | 1 | 2014 | 1123 | 0.230 |
Why?
| | Anxiety Disorders | 2 | 2005 | 373 | 0.220 |
Why?
| | Hydrocortisone | 1 | 2006 | 308 | 0.220 |
Why?
| | Administration, Sublingual | 1 | 2004 | 12 | 0.210 |
Why?
| | Mood Disorders | 1 | 2005 | 139 | 0.210 |
Why?
| | Teaching | 1 | 2005 | 233 | 0.200 |
Why?
| | Male | 25 | 2018 | 69893 | 0.200 |
Why?
| | Quinolones | 1 | 2005 | 173 | 0.200 |
Why?
| | Cocaine | 2 | 2009 | 172 | 0.200 |
Why?
| | Diagnosis, Dual (Psychiatry) | 2 | 2017 | 39 | 0.200 |
Why?
| | Middle Aged | 19 | 2017 | 34487 | 0.190 |
Why?
| | Anticonvulsants | 1 | 2005 | 223 | 0.190 |
Why?
| | Psychiatry | 1 | 2005 | 186 | 0.190 |
Why?
| | Piperazines | 1 | 2005 | 371 | 0.190 |
Why?
| | Cheese | 3 | 2016 | 7 | 0.190 |
Why?
| | Signal Transduction | 1 | 2015 | 5148 | 0.180 |
Why?
| | Postoperative Care | 1 | 2004 | 280 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2018 | 2056 | 0.180 |
Why?
| | Irritable Mood | 1 | 2022 | 50 | 0.180 |
Why?
| | Learning | 1 | 2005 | 434 | 0.170 |
Why?
| | Depressive Disorder, Treatment-Resistant | 1 | 2020 | 13 | 0.170 |
Why?
| | Adaptation, Psychological | 1 | 2006 | 678 | 0.170 |
Why?
| | Prognosis | 3 | 2018 | 4060 | 0.170 |
Why?
| | Adult | 18 | 2017 | 39134 | 0.160 |
Why?
| | Lactobacillus helveticus | 2 | 2009 | 2 | 0.160 |
Why?
| | Brain Injuries | 1 | 2005 | 502 | 0.160 |
Why?
| | Psychiatric Status Rating Scales | 3 | 2006 | 552 | 0.150 |
Why?
| | Animals | 8 | 2019 | 37579 | 0.150 |
Why?
| | Antidepressive Agents | 2 | 2020 | 243 | 0.150 |
Why?
| | DNA Transposable Elements | 2 | 2009 | 120 | 0.140 |
Why?
| | Injections, Intraventricular | 1 | 2018 | 55 | 0.140 |
Why?
| | Alcohol Abstinence | 1 | 2018 | 13 | 0.140 |
Why?
| | Injections, Intraperitoneal | 1 | 2018 | 114 | 0.140 |
Why?
| | Binge-Eating Disorder | 1 | 2018 | 32 | 0.140 |
Why?
| | Neuroimmunomodulation | 1 | 2018 | 65 | 0.140 |
Why?
| | Brain Chemistry | 1 | 2018 | 115 | 0.140 |
Why?
| | Medical History Taking | 1 | 2018 | 117 | 0.140 |
Why?
| | Mice, Inbred C57BL | 3 | 2018 | 5895 | 0.130 |
Why?
| | Bupropion | 1 | 2017 | 45 | 0.130 |
Why?
| | Female | 20 | 2017 | 75540 | 0.130 |
Why?
| | Drug Substitution | 1 | 2017 | 60 | 0.130 |
Why?
| | Comorbidity | 4 | 2017 | 1658 | 0.130 |
Why?
| | Depression | 1 | 2006 | 1487 | 0.120 |
Why?
| | Guidelines as Topic | 1 | 2018 | 268 | 0.120 |
Why?
| | Volatile Organic Compounds | 1 | 2016 | 61 | 0.120 |
Why?
| | Community Mental Health Services | 2 | 2006 | 86 | 0.120 |
Why?
| | Probability | 2 | 2006 | 308 | 0.110 |
Why?
| | Internship and Residency | 1 | 2005 | 1222 | 0.110 |
Why?
| | Severity of Illness Index | 1 | 2023 | 2898 | 0.110 |
Why?
| | Patient Selection | 1 | 2018 | 684 | 0.100 |
Why?
| | Health Facilities | 1 | 2014 | 82 | 0.100 |
Why?
| | Cooperative Behavior | 2 | 2006 | 455 | 0.100 |
Why?
| | Delivery of Health Care, Integrated | 2 | 2006 | 290 | 0.100 |
Why?
| | Hospitals, Veterans | 4 | 2006 | 255 | 0.090 |
Why?
| | Treatment Outcome | 4 | 2022 | 11125 | 0.090 |
Why?
| | Veterans | 4 | 2017 | 1520 | 0.090 |
Why?
| | Follow-Up Studies | 4 | 2006 | 5194 | 0.090 |
Why?
| | Self Administration | 1 | 2012 | 126 | 0.090 |
Why?
| | Bacterial Typing Techniques | 2 | 2009 | 44 | 0.090 |
Why?
| | Sucrose | 1 | 2012 | 111 | 0.090 |
Why?
| | United States | 7 | 2017 | 15195 | 0.090 |
Why?
| | Mice | 3 | 2018 | 18057 | 0.090 |
Why?
| | Amphetamine-Related Disorders | 1 | 2011 | 45 | 0.090 |
Why?
| | Benzhydryl Compounds | 1 | 2011 | 76 | 0.080 |
Why?
| | Patient Care Team | 2 | 2006 | 664 | 0.080 |
Why?
| | Neoplasms | 1 | 2006 | 2718 | 0.080 |
Why?
| | Methamphetamine | 1 | 2011 | 67 | 0.080 |
Why?
| | Drug Interactions | 1 | 2012 | 403 | 0.080 |
Why?
| | Ligands | 1 | 2012 | 667 | 0.080 |
Why?
| | Central Nervous System Stimulants | 1 | 2011 | 177 | 0.080 |
Why?
| | DNA Fingerprinting | 1 | 2009 | 29 | 0.080 |
Why?
| | Pilot Projects | 2 | 2005 | 1815 | 0.080 |
Why?
| | Baclofen | 1 | 2009 | 20 | 0.080 |
Why?
| | Genome, Bacterial | 1 | 2009 | 150 | 0.070 |
Why?
| | Calcium | 1 | 2014 | 1190 | 0.070 |
Why?
| | Psychology | 2 | 2006 | 89 | 0.070 |
Why?
| | Temperance | 1 | 2007 | 21 | 0.070 |
Why?
| | DNA, Bacterial | 1 | 2009 | 333 | 0.070 |
Why?
| | Liver | 2 | 2007 | 1815 | 0.070 |
Why?
| | Interpersonal Relations | 1 | 2010 | 407 | 0.070 |
Why?
| | Liver Function Tests | 1 | 2007 | 105 | 0.070 |
Why?
| | Behavior Therapy | 2 | 2009 | 282 | 0.070 |
Why?
| | Intensive Care Units | 1 | 2013 | 869 | 0.060 |
Why?
| | Liver Failure | 1 | 2007 | 80 | 0.060 |
Why?
| | Disease Management | 1 | 2010 | 628 | 0.060 |
Why?
| | Patient Acceptance of Health Care | 1 | 2013 | 876 | 0.060 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2006 | 136 | 0.060 |
Why?
| | Esters | 1 | 2006 | 77 | 0.060 |
Why?
| | Evolution, Molecular | 1 | 2009 | 505 | 0.060 |
Why?
| | Skull | 1 | 2006 | 147 | 0.060 |
Why?
| | Carbamazepine | 1 | 2005 | 20 | 0.060 |
Why?
| | Education | 1 | 2005 | 108 | 0.060 |
Why?
| | Saliva | 1 | 2006 | 245 | 0.060 |
Why?
| | History, 20th Century | 1 | 2006 | 325 | 0.050 |
Why?
| | Linear Models | 1 | 2007 | 854 | 0.050 |
Why?
| | Aspartate Aminotransferases | 1 | 2004 | 86 | 0.050 |
Why?
| | Genomics | 1 | 2009 | 810 | 0.050 |
Why?
| | Regression Analysis | 1 | 2006 | 1015 | 0.050 |
Why?
| | Alanine Transaminase | 1 | 2004 | 150 | 0.050 |
Why?
| | Practice Guidelines as Topic | 3 | 2006 | 1536 | 0.050 |
Why?
| | Chi-Square Distribution | 1 | 2004 | 521 | 0.050 |
Why?
| | Social Support | 1 | 2007 | 629 | 0.050 |
Why?
| | Diagnostic and Statistical Manual of Mental Disorders | 1 | 2004 | 238 | 0.050 |
Why?
| | Statistics, Nonparametric | 1 | 2004 | 432 | 0.050 |
Why?
| | Survival Analysis | 1 | 2006 | 1320 | 0.050 |
Why?
| | Fatty Acids | 1 | 2006 | 448 | 0.050 |
Why?
| | Minority Groups | 1 | 2005 | 277 | 0.050 |
Why?
| | Actinomycetales | 1 | 2002 | 3 | 0.050 |
Why?
| | Neoplasm Staging | 1 | 2006 | 1396 | 0.050 |
Why?
| | Combined Modality Therapy | 3 | 2011 | 1240 | 0.050 |
Why?
| | Aged | 3 | 2014 | 24666 | 0.050 |
Why?
| | Prospective Studies | 2 | 2005 | 7749 | 0.040 |
Why?
| | Quality of Life | 2 | 2020 | 3005 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2005 | 553 | 0.040 |
Why?
| | United States Department of Veterans Affairs | 1 | 2005 | 711 | 0.040 |
Why?
| | Motivation | 1 | 2005 | 599 | 0.040 |
Why?
| | Health Status | 1 | 2005 | 820 | 0.040 |
Why?
| | Retrospective Studies | 3 | 2013 | 16315 | 0.040 |
Why?
| | Outpatients | 1 | 2003 | 418 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2003 | 398 | 0.040 |
Why?
| | Risk Factors | 3 | 2013 | 10430 | 0.040 |
Why?
| | Curriculum | 1 | 2005 | 1029 | 0.040 |
Why?
| | Reducing Agents | 1 | 2016 | 4 | 0.030 |
Why?
| | Drug Resistance | 1 | 2017 | 149 | 0.030 |
Why?
| | Time Factors | 2 | 2006 | 6944 | 0.030 |
Why?
| | Remission Induction | 1 | 2017 | 309 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 369 | 0.030 |
Why?
| | Oxidants | 1 | 2016 | 111 | 0.030 |
Why?
| | Case Management | 2 | 2006 | 66 | 0.030 |
Why?
| | Sodium Chloride | 1 | 2016 | 140 | 0.030 |
Why?
| | Substance-Related Disorders | 1 | 2005 | 1093 | 0.030 |
Why?
| | Health Plan Implementation | 2 | 2006 | 142 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2016 | 556 | 0.030 |
Why?
| | Patient Readmission | 2 | 2013 | 707 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 1038 | 0.030 |
Why?
| | Taste | 1 | 2016 | 230 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2006 | 3724 | 0.030 |
Why?
| | Rheology | 1 | 2014 | 96 | 0.030 |
Why?
| | Solubility | 1 | 2014 | 244 | 0.030 |
Why?
| | Continuity of Patient Care | 2 | 2006 | 284 | 0.030 |
Why?
| | Health Services Accessibility | 3 | 2006 | 1020 | 0.030 |
Why?
| | Cost-Benefit Analysis | 2 | 2006 | 609 | 0.030 |
Why?
| | Self Care | 2 | 2006 | 392 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2016 | 1086 | 0.020 |
Why?
| | Patient Education as Topic | 2 | 2006 | 772 | 0.020 |
Why?
| | Patient Dropouts | 1 | 2011 | 65 | 0.020 |
Why?
| | Psychotherapy, Group | 1 | 2011 | 74 | 0.020 |
Why?
| | DNA Restriction-Modification Enzymes | 1 | 2009 | 1 | 0.020 |
Why?
| | Chronic Disease | 2 | 2006 | 1811 | 0.020 |
Why?
| | Comparative Genomic Hybridization | 1 | 2009 | 29 | 0.020 |
Why?
| | GABA Agonists | 1 | 2009 | 19 | 0.020 |
Why?
| | Cohort Studies | 2 | 2013 | 5789 | 0.020 |
Why?
| | Survivors | 1 | 2013 | 501 | 0.020 |
Why?
| | Food Microbiology | 1 | 2009 | 72 | 0.020 |
Why?
| | Multigene Family | 1 | 2009 | 202 | 0.020 |
Why?
| | Limbic System | 1 | 2009 | 52 | 0.020 |
Why?
| | Placebos | 1 | 2009 | 195 | 0.020 |
Why?
| | Employment | 1 | 2009 | 179 | 0.020 |
Why?
| | Medication Adherence | 1 | 2011 | 510 | 0.020 |
Why?
| | Safety | 1 | 2009 | 356 | 0.020 |
Why?
| | Educational Status | 1 | 2009 | 462 | 0.020 |
Why?
| | Counseling | 1 | 2009 | 395 | 0.010 |
Why?
| | Calibration | 1 | 2006 | 152 | 0.010 |
Why?
| | Pensions | 1 | 2005 | 4 | 0.010 |
Why?
| | Mental Status Schedule | 1 | 2005 | 34 | 0.010 |
Why?
| | Public Sector | 1 | 2005 | 18 | 0.010 |
Why?
| | Combat Disorders | 1 | 2005 | 41 | 0.010 |
Why?
| | Personality Assessment | 1 | 2005 | 88 | 0.010 |
Why?
| | Interview, Psychological | 1 | 2005 | 96 | 0.010 |
Why?
| | Statistics as Topic | 1 | 2005 | 298 | 0.010 |
Why?
| | Cross-Sectional Studies | 2 | 2005 | 5645 | 0.010 |
Why?
| | California | 1 | 2005 | 455 | 0.010 |
Why?
| | Disability Evaluation | 1 | 2005 | 303 | 0.010 |
Why?
| | Random Amplified Polymorphic DNA Technique | 1 | 2002 | 3 | 0.010 |
Why?
| | Electrophoresis, Gel, Pulsed-Field | 1 | 2002 | 24 | 0.010 |
Why?
| | DNA, Ribosomal | 1 | 2002 | 94 | 0.010 |
Why?
| | Staphylococcus | 1 | 2002 | 75 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2009 | 3336 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2006 | 1968 | 0.010 |
Why?
| | Ambulatory Care | 1 | 2005 | 584 | 0.010 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2002 | 545 | 0.010 |
Why?
| | Indians, North American | 1 | 2005 | 655 | 0.010 |
Why?
| | Sequence Analysis, DNA | 1 | 2002 | 817 | 0.010 |
Why?
| | Age Factors | 1 | 2005 | 3278 | 0.010 |
Why?
| | Hospitalization | 1 | 2005 | 2261 | 0.010 |
Why?
| | Phenotype | 1 | 2002 | 3172 | 0.010 |
Why?
|
|
Beresford's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|